Abstract
Abbreviations: GIA, gastrointestinal aspergillosis; GIT, gastrointestinal tract; IA, invasive aspergillosis; IFI, invasive fungal infection; RAPD, random amplification of polymorphic DNA.
|
The isolates of A. flavus from both sputa and stools were subjected to molecular analysis in order to investigate whether they were genetically identical. The following strains were used for analysis: isolate from sputum, MCCL (Mycology Culture Collection Laboratory, Chandigarh) 760423; isolate from stool, MCCL 760424; standard strain, A. flavus ATCC 16883. Whole-cell DNA from the mycelial form of each isolate was extracted following a slightly modified protocol of a small-scale fungal DNA extraction method (Lee & Taylor, 1990). For evaluating the genetic relatedness of these strains, the genomic DNA was at first analysed by a RFLP assay using restriction enzymes EcoRI and PstI. Separate reactions were set up for each enzyme according to its properties. Approximately 5 µg genomic DNA was subjected to digestion by 10 U of each enzyme in a 30 µl reaction volume. The incubation time and other reaction conditions were standardized for individual enzymes.
The oligonucleotide primers R-108 5'-GTATTGCCCT-3' (Anderson et al., 1996) and R151 5'-GCTGTAGTGT-3' (Lin et al., 1995) were used to perform the random amplification of polymorphic DNA (RAPD) assay. Fifty-microlitre reactions were set up with 100 ng genomic DNA, 3 U Taq DNA polymerase, 200 µM dNTP mix, 2.5 mM MgCl2 and 50 pmol primer R-108/R151. The reaction mixture was subjected to an initial denaturation of 94 °C for 5 min, followed by 30 cycles of 94 °C for 1 min, 36 °C for 1 min and 72 °C for 1 min. A final extension step of 72 °C for 10 min was also included. The amplicons were resolved by electrophoresis through a 1 % (w/v) agarose gel. Isolates were considered similar when the pattern obtained was the same. The isolates from both the sites were genetically identical as determined by RFLP (data not shown) and RAPD analyses (Fig. 2).
|
IA is a life-threatening infection for which early and aggressive multidisciplinary treatment is crucial (Denning et al., 2003). Optimal therapy involves antifungal agents and surgery, along with measures to improve the immune status of the host. Antifungal agents that are currently used to treat aspergillosis are amphotericin B, voriconazole, itraconazole and caspofungin (Denning et al., 2003; Stevens et al., 2000). The clinical response to an antifungal agent may not be adequate, either because the MIC of the agent to the isolate may be high (Lass-Florl et al., 1997) or because the agent may not attain adequate tissue levels (Paterson et al., 2003). In this case, as the MIC of amphotericin B to A. flavus was 2.0 µg ml1, we feel that the organism was less susceptible and therefore responded only to a higher dose [2 mg (kg body weight)1] of the drug. Patients with haematological malignancies are at highest risk of developing a life-threatening relapse of IA during a subsequent course of cytotoxic chemotherapy (Buchheidt et al., 2000; Working Party of British Society for Antimicrobial Chemotherapy, 1993). IA did not recur during the second course of chemotherapy, probably because chemoprophylaxis with itraconazole was effective. On follow up nearly 3 years after the episode, the patient still lives without evidence of leukaemia or IFI.
Standards of high-quality care for a multidisciplinary approach to diagnosis and management of IFI have been very rightly proposed in a review (Denning et al., 2003). Our present case stresses one point of the review that microscopic examination of the clinical material is very useful, especially in diagnosing IFI, and can at times be life saving. The presence of pseudohyphal forms in the microscopic examination of stools is being taken as indirect evidence of invasive candidiasis in cancer patients at our centre. Surveillance fungal cultures of stools in high-risk patients are routinely taken at some centres. Although the use of faecal cultures cannot be advocated to diagnose hyalohyphomycosis, a mould isolated from the faeces of an immunocompromised patient may be a significant finding and should not be automatically dismissed as a contaminant (Schell & Perfect, 1996). The demonstration of fungal hyphae in sputa and stools microscopically, their speciation by culture, their molecular characterization, their in vitro MIC results and the clinical response to antifungal therapy provided strong evidence for a case of disseminated IA involving the GIT and the lungs, even in the absence of histopathological proof. Aspergillus infection should be considered in the differential diagnosis of gastrointestinal complications in patients with haematological malignancy. A high index of suspicion, prompt diagnosis and early institution of aggressive antifungal therapy can cure immunocompromised patients with IA without the need for surgery, provided there is resolution of neutropenia.
We would like to express our sincere thanks to Dr S. K. Shankar, Professor, Department of Neuropathology, National Institute of Mental Health and Neurosciences, Bangalore, India, for microphotography.References
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E. & 16 other authors (2002). Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hemopoeitic stem cell transplants: an international consensus. Clin Infect Dis 34, 714.[CrossRef][Medline]
Austwick, P. K. C. (1965). Pathogenicity. In The Genus Aspergillus, pp. 82126. Edited by K. B. Raper & D. I. Fennell. Baltimore: Williams & Wilkins.
Buchheidt, D., Skladny, H., Baust, C. & Hehlmann, R. (2000). Systemic infections with Candida sp. and Aspergillus sp. in immunocompromised patients with hematological malignancies: current serological and molecular diagnostic methods. Chemotherapy 46, 219228.[Medline]
Denning, D. W. & Stevens, D. A. (1990). Antifungal and surgical treatment of invasive aspergillosis. Review of 2,121 published cases. Rev Infect Dis 12, 11471201.[Medline]
Denning, D. W., Kibbler, C. C. & Barnes, R. A. (2003). British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 3, 230240.[CrossRef][Medline]
Hori, A., Kami, M., Kishi, Y., Mashid, U., Matsumura, T. & Kashima, T. (2002). Clinical significance of extra-pulmonary involvement of invasive aspergillosis: a retrospective autopsy-based study of 107 patients. J Hosp Infect 50, 175182.[Medline]
Lass-Florl, C., Kofler, G., Kropshofer, G., Hermans, J., Kreczy, A., Dierich, M. P. & Niederwieser, D. (1997). In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J Antimicrob Chemother 40, 401414.
Lee, S. B. & Taylor, J. W. (1990). Isolation of DNA from fungal mycelia and single spores. In PCR Protocols: a Guide to Methods and Applications, pp. 282287. Edited by M. A. Innis, D. H. Gelfand, J. J. Sninsky & T. J. White. San Diego: Academic Press.
Lin, D., Lehmann, P. F., Hamory, B. H., Padhye, A. A., Durry, E., Pinner, R. W. & Lasker, B. A. (1995). Comparison of three typing methods for clinical and environmental isolates of Aspergillus fumigatus. J Clin Microbiol 33, 15961601.[Abstract]
National Committee for Clinical Laboratory Standards (2002). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Approved standard M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards.
Paterson, P. J., Seaton, S., Prentice, H. G. & Kibbler, C. C. (2003). Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 52, 873876.
Prescott, R. J., Harris, M. & Banerjee, S. S. (1992). Fungal infections of the small and large intestine. J Clin Pathol 45, 806811.
Richter, S., Cormican, M. G., Pfaller, M. A., Lee, C. K., Gingrich, R., Rinaldi, M. G. & Sutton, D. A. (1999). Fatal disseminated Trichoderma longibrachiatum infection in an adult bone marrow transplant patient: species identification and review of the literature. J Clin Microbiol 37, 11541160.
Schell, W. A. & Perfect, J. R. (1996). Fatal, disseminated Acremonium strictum infection in a neutropenic host. J Clin Microbiol 34, 13331336.[Abstract]
Soll, D. R. (2000). The ins and outs of DNA fingerprinting the infectious fungi. Clin Microbiol Rev 13, 332370.
Srivastava, V. M., Krishnaswami, H., Srivastava, A., Dennison, D. & Chandy, M. (1996). Infections in haematological malignancies: an autopsy study of 72 cases. Trans R Soc Trop Med Hyg 90, 406408.[CrossRef][Medline]
Stevens, D. A., Kan, V. L., Judson, M. A. & 7 other authors (2000). Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 30, 696709.[CrossRef][Medline]
Working Party of British Society for Antimicrobial Chemotherapy (1993). Chemoprophylaxis for candidiosis and aspergillosis in neutropenia and transplantation review and recommendations. J Antimicrob Chemother 32, 521.
Wright, J. A., Bradfield, S. M., Park, J. R. & Hawkins, D. S. (2003). Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases. J Pediatr Hematol Oncol 25, 286291.[Medline]
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| INT J SYST EVOL MICROBIOL | J MED MICROBIOL | MICROBIOLOGY | J GEN VIROL | ALL SGM JOURNALS |